CDCA8

Across TCGA pan-cancer cohorts, CDCA8 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDCA8 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CDCA8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDCA8 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where CDCA8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.918	0.566	.002	8	view →
PDAC	DFS	Median	All	0.609	1.000	.036	4	view →
CCRCC	DFS	Median	II,III,IV	0.420	1.000	.036	2	view →
GBM	OS	Median	All	0.691	0.248	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDCA8–LSCC (OS)

Open the LSCC breakdown →